Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.2%

1 terminated out of 46 trials

Success Rate

96.3%

+9.8% vs benchmark

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

19%

5 of 26 completed with results

Key Signals

5 with results96% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (8)
P 1 (10)
P 2 (1)
P 4 (5)

Trial Status

Completed26
Recruiting8
Unknown7
Active Not Recruiting2
Terminated1
Enrolling By Invitation1

Trial Success Rate

96.3%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT02640014Not ApplicableCompleted

Oral Immunotherapy in Food Allergy in Finland

NCT07210320Phase 1Completed

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

NCT07038746Phase 1Recruiting

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

NCT07341776Phase 4Recruiting

Steroid Use in Treatment of Allergic Reactions to Food

NCT07328178RecruitingPrimary

Analysis of the Role of IgE Proteoforms in Health and Disease

NCT06793163Recruiting

Diagnosis and Allergen Identification of Perioperative Anaphylaxis

NCT07231393Completed

Observation Periods and Biphasic Reaction Risk Factors in Pediatric Emergency Anaphylaxis Cases

NCT07228325Phase 1Enrolling By InvitationPrimary

Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

NCT06065137Not ApplicableCompleted

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

NCT06963411Phase 1Completed

Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers

NCT06445374Phase 1Completed

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

NCT07027163Completed

A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

NCT06205134Phase 1CompletedPrimary

Comparative Bioavailability of Intranasal Epinephrine

NCT05135377Active Not RecruitingPrimary

Canadian Anaphylaxis Network- Predicting Recurrence After Emergency Presentation for Allergic REaction

NCT04653324Recruiting

A Registry for the Food Allergy Community

NCT05210543RecruitingPrimary

Acquisition and Long-term Observation of Patients With Severe Allergic Reactions

NCT03523221Phase 1RecruitingPrimary

Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis

NCT04615065Recruiting

Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine

NCT04696822Phase 1CompletedPrimary

Bioavailability of Nasal Epinephrine

NCT03953482UnknownPrimary

Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis

Scroll to load more

Research Network

Activity Timeline